The Cellvizio® 100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image...
Clinical trial published in peer-reviewed journal demonstrates diagnostic yield from Cellvizio® significantly exceeds standard of care (84.1% vs...
Mauna Kea Technologies today announced a strategic equity investment of 7.5 million euro by Johnson & Johnson Innovation – JJDC, Inc....
MEDPHOT consortium aims to develop light-based molecular imaging solution for pulmonary diseases Mauna Kea Technologies today announced...
READ THE COMPLETE PRESS RELEASE
Three recent clinical publications demonstrate that Cellvizio® AQ-Flex™ 19 Confocal Miniprobe significantly improves...
READ THE COMPLETE PRESS RELEASE
READ THE COMPLETE PRESS RELEASE
Q2 Sales up 33% year-over-year & First Half 2019 sales up 45% year-over-year. Consumables sales represent the largest driver of growth in both...
Mauna Kea Technologies announces today that it has received the first tranche of €11.5 million (Tranche 1), under a financing agreement...
Mauna Kea Technologies and the European Investment Bank (EIB), which is the Bank of the European Union (EU), announce the signing of a 22.5 million...
Announcement of the creation of a new specific procedural code to be added to the Common Classification of Medical Procedures (CCAM) published in...
